Abstract 3607
Background
We aimed to establish a prognostic model based on magnetic resonance imaging using deep learning to predict disease-free survival in patients with non-metastatic nasopharyngeal carcinoma.
Methods
In this retrospective, cohort study, we included 1636 patients who were diagnosed with non-metastatic nasopharyngeal carcinoma and underwent radical treatment at the Sun Yat-sen University Cancer Center. Patients from October 2010 to March 2015 were randomly divided into training cohort (n = 878) and validation cohort (n = 376); 382 patients from April 2015 to September 2015 were separated as test cohort. 3D DenseNet models learned deep representations of pre-treatment MRI and risk scores were extracted to predict PFS in the training cohort. We evaluated the accuracy of the prognostic model in validation and test cohorts. The primary endpoint was DFS, and the secondary endpoint was distant metastasis-free survival (DMFS).
Results
A series of risk scores for each patient were extracted from 3D DenseNet models, and an optimal cut-off value of risk scores was generated to classify patients into low-risk and high-risk group in the training cohort. Patients with low-risk scores had better DFS (hazard ratio [HR] 0.62, 95% CI 0.55 -0.70; p < 0.0001) and DMFS (HR 0.62, 95% CI 0.48 -0.81; p < 0.0003) than patients with low-risk scores. And we validated the prognostic accuracy of risk scores in the validation and test cohorts. In addition, patients who received concurrent chemotherapy had a poorer DFS (hazard ratio [HR] 7.79, 95% CI 1.08 -56.00; p < 0.041) compared with those who did not receive concurrent chemotherapy in low-risk group, meanwhile, patients with or without concurrent chemotherapy had similar outcomes in the high-risk group (HR 2.39, 95% CI 0.59 -9.62; p = 0.22). We also developed a nomogram based on risk scores and several clinical factors that predicted an individual’s risk of DFS.
Conclusions
MRI-based 3D DenseNet models are effective tools to learn deep representations and extract risk scores of DFS. Risk scores can be reliable prognostic factors to select which patients benefit from concurrent chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract